Advaxis and the Icahn School of Medicine at Mount Sinai (ISMMS) will begin a Phase I/II study of ADXS-HPV in 25 patients with Human Papilloma Virus (HPV)-positive head and neck cancer. This trial will be the first study to evaluate the effects of ADXS-HPV in patients when they are initially diagnosed with HPV-associated head and neck cancer, prior to receiving any chemotherapy or radiation. This study will be an important first step toward understanding ADXS-HPV’s potential to treat this t...